Amplification of the ATP-Binding Cassette 2 Transporter Gene Is Functionally Linked with Enhanced Efflux of Estramustine in Ovarian Carcinoma Cells1
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT (51) International Patent Classification: A61K 31/53 (2006 .01) A61P 35/00 (2006 .0 1) C07D 251/40 (2006.01) (21) International Application Number: PCT/US20 18/024 134 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/476,585 24 March 2017 (24.03.2017) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US). (72) Inventors: NOMURA, Daniel, K.; 4532 Devenport Av enue, Berkeley, CA 94619 (US). ANDERSON, Kimberly, E.; 8 Marchant Court, Kensington, CA 94707 (US). (74) Agent: LEE, Joohee et al; Mintz Levin Cohn Ferris Glovsky And Popeo, P.C., One Financial Center, Boston, MA 021 11 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. -
Recent Advances in the Management of Hormone Refractory Prostate Cancer
Korean J Uro-Oncol 2004;2(3):147-153 Recent Advances in the Management of Hormone Refractory Prostate Cancer Mari Nakabayashi, William K. Oh Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA A typical treatment strategy after AAWD is to use secondary INTRODUCTION hormonal manipulations, although studies have not yet demonstrated a survival benefit with this class of treatment. Prostate cancer is the most common cancer in men in the Options in this category include (1) the secondary use of anti- United States and accounted for 29,900 deaths in 2003.1 androgens (e.g., high-dose bicalutamide, nilutamide), (2) thera- Although most men with advanced prostate cancer respond pies targeted against adrenal steroid synthesis (e.g., ketocona- initially to androgen deprivation therapies (ADT) by either zole, corticosteroids), and (3) estrogenic therapies (e.g. diethy- bilateral orchiectomy or leuteinizing hormone releasing hor- lstilbestrol). Symptomatic improvement and PSA responses mone (LHRH) analogues, patients eventually progress to an (defined as PSA decline >50% after treatment) have been androgen-independent state in which the initial ADT no longer reported in approximately 20% to 80% of patients with is adequate to control disease.2 Progression of the disease hormone-refractory prostate cancer (HRPC) with a typical manifests as an increase in serum prostate-specific antigen duration of response of 2 to 6 months. Toxicity is generally (PSA) or may be accompanied by radiographic evidence of mild for these oral therapies, although serious side effects, tumor growth. Here we report a brief summary of recent including adrenal insufficiency, liver toxicity, and thrombosis, advances in the management of hormone refractory prostate may occur (Table 1). -
Cumulative Cross Index to Iarc Monographs
PERSONAL HABITS AND INDOOR COMBUSTIONS volume 100 e A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 29 September-6 October 2009 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS The volume, page and year of publication are given. References to corrigenda are given in parentheses. A A-α-C .............................................................40, 245 (1986); Suppl. 7, 56 (1987) Acenaphthene ........................................................................92, 35 (2010) Acepyrene ............................................................................92, 35 (2010) Acetaldehyde ........................36, 101 (1985) (corr. 42, 263); Suppl. 7, 77 (1987); 71, 319 (1999) Acetaldehyde associated with the consumption of alcoholic beverages ..............100E, 377 (2012) Acetaldehyde formylmethylhydrazone (see Gyromitrin) Acetamide .................................... 7, 197 (1974); Suppl. 7, 56, 389 (1987); 71, 1211 (1999) Acetaminophen (see Paracetamol) Aciclovir ..............................................................................76, 47 (2000) Acid mists (see Sulfuric acid and other strong inorganic acids, occupational exposures to mists and vapours from) Acridine orange ...................................................16, 145 (1978); Suppl. 7, 56 (1987) Acriflavinium chloride ..............................................13, -
(12) Patent Application Publication (10) Pub. No.: US 2008/0317850 A1 Hewitt Et Al
US 20080317850A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317850 A1 Hewitt et al. (43) Pub. Date: Dec. 25, 2008 (54) BUCCAL DELIVERY SYSTEM Publication Classification (51) Int. Cl. (76) Inventors: Ernest Alan Hewitt, New South A69/20 (2006.01) Wales (AU); Richard James A6II 47/34 (2006.01) Stenlake, New South Wales (AU) A 6LX 3/57 (2006.01) A6II 3/565 (2006.01) Correspondence Address: A6II 3/568 (2006.01) REED SMITH LLP A6II 3/66 (2006.01) P.O. BOX 488 (52) U.S. Cl. ......... 424/464; 424/486; 514/177: 514/182: PITTSBURGH, PA 15230-0488 (US) 514/178; 514/108 (57) ABSTRACT (21) Appl. No.: 11/910,902 A buccal delivery system capable of being blended in a nor 1-1. mal dry powder process and compressed using a standard (22) PCT Filed: Apr. 7, 2006 tabletting machine, said buccal delivery system comprising a matrix of: (a) an effective amount of one or more active (86). PCT No.: PCT/AU2OO6/OOO472 ingredients; (b) an amount of one or more polyethylene gly cols orderivatives thereofhaving a molecular weight between S371 (c)(1), 1000 to 8000 sufficient to provide the required hardness and (2), (4) Date: Feb. 5, 2008 time for dissolution of the matrix; (c) 0.05-2% by weight of the total matrix of one or more Suspending agents; (d) 0.05 (30) Foreign Application Priority Data 2% by weight of the total matrix of one or more flowing agents; and (e) 0.05-2% by weight of the total matrix of one or Apr. -
Meo Meo C Meo US 6,794,384 B1 Page 2
USOO6794384B1 (12) United States Patent (10) Patent No.: US 6,794,384 B1 Potter et al. (45) Date of Patent: Sep. 21, 2004 (54) HYDROXYLATION ACTIVATED DRUG 6,214,886 B1 4/2001 Potter et al. ................ 514/685 RELEASE 6,346,550 B2 2/2002 Potter et al. ...... ... 514/685 2002/0037296 A1 3/2002 Potter et al. ................ 424/400 (75) Inventors: Gerard Andrew Potter, Leicester (GB); Lawrence Hylton Patterson, FOREIGN PATENT DOCUMENTS Leicester (GB); Michael Danny Burke, CA 2109259 4/1994 Leicester (GB) DE 4309344 9/1949 DE 4236237 4/1994 (73) Assignee: De Montfort University, Leicester EP O322 738 A2 7/1989 EP O642799 3/1995 (GB) JP 56/O16474 A2 * 2/1981 JP 56O16474 2/1981 ......... CO7D/239/54 (*) Notice: Subject to any disclaimer, the term of this JP 61076433 4/1986 patent is extended or adjusted under 35 JP O81885.46 7/1996 U.S.C. 154(b) by 0 days. WO 971.2246 4/1997 WO WO 99/40056 8/1999 (21) Appl. No.: 09/633,697 WO WO 99/40944 8/1999 (22) Filed: Aug. 7, 2000 OTHER PUBLICATIONS Draetta, G. and Pagano, M. in “Annual Reports in Medicinal Related U.S. Application Data Chemistry, vol. 31, 1996, Academic Press, San Diego, p (63) Continuation of application No. PCT/GB99/00416, filed on 241-248. Feb. 10, 1999. Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975–977.* (30) Foreign Application Priority Data Banker, G.S. et al., “Modern Pharmaceutics, 3ed.'', Marcel Feb. 12, 1998 (GB) ............................................. 98O2957 Dekker, New York, 1996, p. -
(12) United States Patent (10) Patent No.: US 6,265,147 B1 Mobley Et Al
USOO6265147B1 (12) United States Patent (10) Patent No.: US 6,265,147 B1 Mobley et al. (45) Date of Patent: Jul. 24, 2001 (54) METHOD OF SCREENING FOR Carmeci, Charles, et al., “Identification of a Gene (GPR30) NEUROPROTECTIVE AGENTS with Homology to the G-Protein-Coupled Receptor Super family ASSociated with Estrogen Receptor Expression in (75) Inventors: William C. Mobley, Palo Alto; Ronald Breast Cancer,” Genomics (1997) vol. 45:607-617. J. Weigel, Woodside; Chengbiao Wu, Owman, Christer, et al., “Cloning of Human cDNA Encod San Jose; Har Hiu Dawn Lam, ing a Novel Hepathelix Receptor Expressed in Burkitt's Stanford, all of CA (US) Lymphoma and Widely Distributed in Brain abd Peripheral Tissues,” Biochemical and Biophysical Research Cimmuni (73) Assignee: The Board of Trustees of the Leland cations (1996) vol. 228:285–292. Stanford Junior University, Palo Alto, Singh, Meharvan, et al., “Estrogen-Induced Activation of CA (US) Mitogen-Activated Protein Kinase in Cerebral Cortical Explants: Convergence of Estrogen and Neurotrophin Sig (*) Notice: Subject to any disclaimer, the term of this naling Pathways,” Journal of Neuroscience (Feb. 15, 1999) patent is extended or adjusted under 35 vol. 19(4): 1179–1188. U.S.C. 154(b) by 0 days. Toran-Allerand, C. Dominique, “The Estrogen/Neurotro phin Connection During Neural Development: Is Co-Lo (21) Appl. No.: 09/452,531 calization of Estrogen Receptors with the Neurotrophins and Their Receptors Biologically Revelant?”, Dev: Neurosci. (22) Filed: Dec. 1, 1999 (1996) vol. 18:36–48. (51) Int. Cl." ................................................... C12O 1/00 Genbank Accession Number Y08162. (52) U.S. Cl. ............................... 435/4; 435/69.1; 514/169 * cited by examiner (58) Field of Search ........................ -
Estramustine Phosphate Inhibits Germinal Vesicle Breakdown and Induces Depolymerization of Microtubules in Mouse Oocyte Hélène Rime, Catherine Jessus, R
Estramustine phosphate inhibits germinal vesicle breakdown and induces depolymerization of microtubules in mouse oocyte Hélène Rime, Catherine Jessus, R. Ozon To cite this version: Hélène Rime, Catherine Jessus, R. Ozon. Estramustine phosphate inhibits germinal vesicle breakdown and induces depolymerization of microtubules in mouse oocyte. Reproduction Nutrition Développe- ment, 1988, 28 (2A), pp.319-334. hal-00898793 HAL Id: hal-00898793 https://hal.archives-ouvertes.fr/hal-00898793 Submitted on 1 Jan 1988 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Estramustine phosphate inhibits germinal vesicle breakdown and induces depolymerization of microtubules in mouse oocyte Hélène RIME Catherine JESSUS R. OZON Laboratoire de Physiologie de la Reproduction, Groupe Stéroides, UA-CNRS 555, Université Pierre et Marie Curie, 4, place Jussieu, 75252 Paris Cedex 05, France. Summary. The first meiotic cell division (meiotic maturation) of the dictyate stage of mouse oocytes, removed from the follicle, resumes spontaneously in vitro. This study indicates that estramustine phosphate reversibly blocks meiotic maturation by inhibiting germinal vesicle breakdown. Oocyte cryostat sections were stained with anti-tubulin and two antibodies (anti-MAP1 : JA2 and 5051) which decorated the metaphase spindle during meiotic maturation. -
Effects of Cancer Chemotherapeutic Agents on Endocrine Organs and Serum Levels of Estrogens, Progesterone, Prolactin, and Luteinizing Hormone'
[CANCER RESEARCH 35, 1975-1980, August 1975] Effects of Cancer Chemotherapeutic Agents on Endocrine Organs and Serum Levels of Estrogens, Progesterone, Prolactin, and Luteinizing Hormone' Eric V. H. Kuo, Henry J. Esber, D. Jane Taylor, and Arthur E. Bogden Department oflmmunobiology, Mason ResearchInstitute, Worcester,Massachusetts01608[E. Y. H. K., H. J. E., A. E. B.], and Division of Cancer Biology and Diagnosis,National CancerInstitute, Bethesda,Maryland 21.Xfl4[D.J. T.] SUMMARY INTRODUCTION The effects of the following cancer chemotherapeutic Many types ofneoplasms, both spontaneous and induced, agents on serum hormonal levels, estrous cycles, and are known to arise in the various endocrine organs as well as endocrine organs were studied in mature, normal in the target tissues of hormones. The growth of tumors Sprague-Dawley rats by radioimmunoassay, vaginal smear arising in endocrine-responsive tissues is frequently found to examination, and organ weight end point: estradiol mustard be hormone dependent or at least hormone responsive. (NSC 112259), testosterone mustard (NSC I 12260), phen Recent studies (9, 11) on gs antigen expression have estrin (NSC 104469), methotrexate (NSC 740), 5-fluo produced evidence suggesting that certain hormones may rouracil (NSC 19893), vinblastine (NSC 49842), vincristine also play a role in activating the oncogenic expression of (NSC 67574), nitrogen mustard (NSC 762), and l,3-bis(2- some RNA tumor virus genomes. While hormonal effects chloroethyl)-l-nitrosourea (NSC 409962). Following 2 are often associated with stimulation of tumor growth, an weeks of treatment, estradiol-17fi levels were markedly inhibitory effect on tumor growth may also be exerted by elevated by all compounds except testosterone mustard and hormones (14, 24). -
Report Versionpdf
THIRD EDITION 2004 Stateof the Evidence What Is the Connection Between the Environment and Breast Cancer? Edited by Nancy Evans, Health Science Consultant, Breast Cancer Fund Dedicated to our founders, pioneers in breast cancer and environmental health ANDREA RAVINETT MARTIN 1946-2003 Breast Cancer Fund ELENORE G. PRED 1933-1991 Breast Cancer Action Cover Illustration: Book of Flowers IX, by Lynda Fishbourne, 1997, “Art.Rage.Us; Art and Writing by Women with Breast Cancer” After I finished chemotherapy and started radiation treatments every day, I also found a new medium, encaustic (wax). It felt like a rebirth in a way. As a reward to myself for my daily hospitals visits, I painted in encaustic every day before leaving for my appointment. A series of these paintings resulted. The darker side has petals falling, and the background is etched with counting; it shows what I was leaving behind. The lighter, sunnier side contains written thoughts as well as flowers and leaves from my walks in nature. It reflects the more positive feelings I was having. Acknowledgments Breast Cancer Fund and Breast Cancer Action wish to thank the following scientific experts who reviewed and commented on State of the Evidence: Devra Lee Davis, Ph.D., M.P.H., Director, Center for Environmental Oncology, University of Pittsburgh Cancer Institute and Professor, Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh. Philip Randolph Lee, M.D., Professor Emeritus, University of California San Francisco School of Medicine, former Assistant Secretary of Health & Human Services, San Francisco, Calif. Annie J. Sasco, M.D., Dr P.H., Chief of the Unit of Epidemiology for Cancer Prevention, International Agency for Research on Cancer and Director of Research, Institut National de la Santé et de la Recherche Médicale, Lyon, France. -